58 related articles for article (PubMed ID: 28178481)
1. Treg Depletion-enhanced IL-2 Treatment Facilitates Therapy of Established Tumors Using Systemically Delivered Oncolytic Virus.
Kottke T; Galivo F; Wongthida P; Maria Diaz R; Thompson J; Jevremovic D; Barber GN; Hall G; Chester J; Selby P; Harrington K; Melcher A; Vile RG
Mol Ther; 2008 Jul; 16(7):1217-1226. PubMed ID: 28178481
[TBL] [Abstract][Full Text] [Related]
2. Treg depletion-enhanced IL-2 treatment facilitates therapy of established tumors using systemically delivered oncolytic virus.
Kottke T; Galivo F; Wongthida P; Diaz RM; Thompson J; Jevremovic D; Barber GN; Hall G; Chester J; Selby P; Harrington K; Melcher A; Vile RG
Mol Ther; 2008 Jul; 16(7):1217-26. PubMed ID: 18431359
[TBL] [Abstract][Full Text] [Related]
3. Use of biological therapy to enhance both virotherapy and adoptive T-cell therapy for cancer.
Kottke T; Diaz RM; Kaluza K; Pulido J; Galivo F; Wongthida P; Thompson J; Willmon C; Barber GN; Chester J; Selby P; Strome S; Harrington K; Melcher A; Vile RG
Mol Ther; 2008 Dec; 16(12):1910-8. PubMed ID: 18827807
[TBL] [Abstract][Full Text] [Related]
4. Improved systemic delivery of oncolytic reovirus to established tumors using preconditioning with cyclophosphamide-mediated Treg modulation and interleukin-2.
Kottke T; Thompson J; Diaz RM; Pulido J; Willmon C; Coffey M; Selby P; Melcher A; Harrington K; Vile RG
Clin Cancer Res; 2009 Jan; 15(2):561-9. PubMed ID: 19147761
[TBL] [Abstract][Full Text] [Related]
5. Oncolytic virus and anti-4-1BB combination therapy elicits strong antitumor immunity against established cancer.
John LB; Howland LJ; Flynn JK; West AC; Devaud C; Duong CP; Stewart TJ; Westwood JA; Guo ZS; Bartlett DL; Smyth MJ; Kershaw MH; Darcy PK
Cancer Res; 2012 Apr; 72(7):1651-60. PubMed ID: 22315352
[TBL] [Abstract][Full Text] [Related]
6. Oncolytic immunovirotherapy for melanoma using vesicular stomatitis virus.
Diaz RM; Galivo F; Kottke T; Wongthida P; Qiao J; Thompson J; Valdes M; Barber G; Vile RG
Cancer Res; 2007 Mar; 67(6):2840-8. PubMed ID: 17363607
[TBL] [Abstract][Full Text] [Related]
7. Combination Therapy With Reovirus and Anti-PD-1 Blockade Controls Tumor Growth Through Innate and Adaptive Immune Responses.
Rajani K; Parrish C; Kottke T; Thompson J; Zaidi S; Ilett L; Shim KG; Diaz RM; Pandha H; Harrington K; Coffey M; Melcher A; Vile R
Mol Ther; 2016 Feb; 24(1):166-74. PubMed ID: 26310630
[TBL] [Abstract][Full Text] [Related]
8. Expressing human interleukin-15 from oncolytic vesicular stomatitis virus improves survival in a murine metastatic colon adenocarcinoma model through the enhancement of anti-tumor immunity.
Stephenson KB; Barra NG; Davies E; Ashkar AA; Lichty BD
Cancer Gene Ther; 2012 Apr; 19(4):238-46. PubMed ID: 22158521
[TBL] [Abstract][Full Text] [Related]
9. Cytokine-secreting herpes viral mutants effectively treat tumor in a murine metastatic colorectal liver model by oncolytic and T-cell-dependent mechanisms.
Derubertis BG; Stiles BM; Bhargava A; Gusani NJ; Hezel M; D'Angelica M; Fong Y
Cancer Gene Ther; 2007 Jun; 14(6):590-7. PubMed ID: 17431402
[TBL] [Abstract][Full Text] [Related]
10. Macrophage depletion combined with anticoagulant therapy increases therapeutic window of systemic treatment with oncolytic adenovirus.
Shashkova EV; Doronin K; Senac JS; Barry MA
Cancer Res; 2008 Jul; 68(14):5896-904. PubMed ID: 18632644
[TBL] [Abstract][Full Text] [Related]
11. Antitumoral immune response by recruitment and expansion of dendritic cells in tumors infected with telomerase-dependent oncolytic viruses.
Edukulla R; Woller N; Mundt B; Knocke S; Gürlevik E; Saborowski M; Malek N; Manns MP; Wirth T; Kühnel F; Kubicka S
Cancer Res; 2009 Feb; 69(4):1448-58. PubMed ID: 19190348
[TBL] [Abstract][Full Text] [Related]
12. Preferential replication of systemically delivered oncolytic vaccinia virus in focally irradiated glioma xenografts.
Advani SJ; Buckel L; Chen NG; Scanderbeg DJ; Geissinger U; Zhang Q; Yu YA; Aguilar RJ; Mundt AJ; Szalay AA
Clin Cancer Res; 2012 May; 18(9):2579-90. PubMed ID: 22379115
[TBL] [Abstract][Full Text] [Related]
13. PolySia-Specific Retargeting of Oncolytic Viruses Triggers Tumor-Specific Immune Responses and Facilitates Therapy of Disseminated Lung Cancer.
Kloos A; Woller N; Gürlevik E; Ureche CI; Niemann J; Armbrecht N; Martin NT; Geffers R; Manns MP; Gerardy-Schahn R; Kühnel F
Cancer Immunol Res; 2015 Jul; 3(7):751-63. PubMed ID: 25701327
[TBL] [Abstract][Full Text] [Related]
14. Intratumoral coadministration of hyaluronidase enzyme and oncolytic adenoviruses enhances virus potency in metastatic tumor models.
Ganesh S; Gonzalez-Edick M; Gibbons D; Van Roey M; Jooss K
Clin Cancer Res; 2008 Jun; 14(12):3933-41. PubMed ID: 18559615
[TBL] [Abstract][Full Text] [Related]
15. Enhanced therapeutic efficacy of IL-12, but not GM-CSF, expressing oncolytic herpes simplex virus for transgenic mouse derived prostate cancers.
Varghese S; Rabkin SD; Liu R; Nielsen PG; Ipe T; Martuza RL
Cancer Gene Ther; 2006 Mar; 13(3):253-65. PubMed ID: 16179929
[TBL] [Abstract][Full Text] [Related]
16. Enhanced antitumor effect of oncolytic adenovirus expressing interleukin-12 and B7-1 in an immunocompetent murine model.
Lee YS; Kim JH; Choi KJ; Choi IK; Kim H; Cho S; Cho BC; Yun CO
Clin Cancer Res; 2006 Oct; 12(19):5859-68. PubMed ID: 17020994
[TBL] [Abstract][Full Text] [Related]
17. Systemic therapy of spontaneous prostate cancer in transgenic mice with oncolytic herpes simplex viruses.
Varghese S; Rabkin SD; Nielsen GP; MacGarvey U; Liu R; Martuza RL
Cancer Res; 2007 Oct; 67(19):9371-9. PubMed ID: 17909046
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant treatment of hepatic malignancy: an oncolytic herpes simplex virus expressing IL-12 effectively treats the parent tumor and protects against recurrence-after resection.
Jarnagin WR; Zager JS; Klimstra D; Delman KA; Malhotra S; Ebright M; Little S; DeRubertis B; Stanziale SF; Hezel M; Federoff H; Fong Y
Cancer Gene Ther; 2003 Mar; 10(3):215-23. PubMed ID: 12637943
[TBL] [Abstract][Full Text] [Related]
19. Strengthening of antitumor immune memory and prevention of thymic atrophy mediated by adenovirus expressing IL-12 and GM-CSF.
Choi KJ; Zhang SN; Choi IK; Kim JS; Yun CO
Gene Ther; 2012 Jul; 19(7):711-23. PubMed ID: 21993173
[TBL] [Abstract][Full Text] [Related]
20. Systemic oncolytic herpes virus therapy of poorly immunogenic prostate cancer metastatic to lung.
Varghese S; Rabkin SD; Nielsen PG; Wang W; Martuza RL
Clin Cancer Res; 2006 May; 12(9):2919-27. PubMed ID: 16675589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
